Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
Sodium-glucose linked transporter (SGLT-2) inhibitors are the most emerging glucose-lowering agents. Predominantly expressed in kidney, SGLT-2 is mainly distributed in upper part of proximal tubule. Mainly responsible for a reabsorption of filtered glucose, it accounts for over 80%-90% of glucose re...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Editorial Department of Journal of Clinical Nephrology,
2023-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_acb50d9ee78348d1a0ec48908c6f40a2 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Feng Liu |e author |
| 700 | 1 | 0 | |a Qing-mei Yang |e author |
| 700 | 1 | 0 | |a Bo Pan |e author |
| 700 | 1 | 0 | |a Xiao-hui Liu |e author |
| 245 | 0 | 0 | |a Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease |
| 260 | |b Editorial Department of Journal of Clinical Nephrology, |c 2023-10-01T00:00:00Z. | ||
| 500 | |a 1671-2390 | ||
| 500 | |a 10.3969/j.issn.1671-2390.2023.10.012 | ||
| 520 | |a Sodium-glucose linked transporter (SGLT-2) inhibitors are the most emerging glucose-lowering agents. Predominantly expressed in kidney, SGLT-2 is mainly distributed in upper part of proximal tubule. Mainly responsible for a reabsorption of filtered glucose, it accounts for over 80%-90% of glucose reabsorption. And SGLT-1 takes up the remainders. SGLT-2 inhibitors act at proximal tubule where they inhibit glucose and sodium reabsorption, thus enhancing urinary sugar excretion and lowering body glucose burden. Several studies have confirmed that SGLT-2 inhibitors might improve the prognoses of renal and cardiovascular disease in diabetics. Also there are significant protective effects on renal system of patients with non-diabetic kidney disease (NDKD). Therefore the induction protection mechanism of SGLT-2 inhibitors on non-diabetic chronic kidney disease (CKD) has attracted growing attention. This review summarized the latest researches of renoprotective mechanism of SGLT-2 inhibitors in NDKD. | ||
| 546 | |a ZH | ||
| 690 | |a sodium-glucose linked transporter | ||
| 690 | |a diabetic kidney disease | ||
| 690 | |a kidney | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Linchuang shenzangbing zazhi, Vol 23, Iss 10, Pp 863-867 (2023) | |
| 787 | 0 | |n http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2023.10.012 | |
| 787 | 0 | |n https://doaj.org/toc/1671-2390 | |
| 856 | 4 | 1 | |u https://doaj.org/article/acb50d9ee78348d1a0ec48908c6f40a2 |z Connect to this object online. |